文献速递自身炎症与 IgG4 相关病

甲氨蝶呤治疗斯蒂尔病患者的「真实世界」发现:来自AIDA网络斯蒂尔病登记处的数据

The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry.
PubMed 文献 · Semin Arthritis Rheum · 2023-07-21

该研究基于AIDA网络斯蒂尔病登记处,描述了171例接受甲氨蝶呤治疗的斯蒂尔病患者的临床特征并评估药物有效性。结果显示甲氨蝶呤可降低疾病活动度、降低炎症标志物及铁蛋白水平,并减少糖皮质激素用量,38.6%患者在研究结束时达到临床缓解,12.3%因不良反应停药、12.3%因疗效不足停药。

要点

  • 甲氨蝶呤治疗患者以关节表现和发热为主,无突出的多器官受累。
  • 38.6%患者在研究结束时达到临床缓解,合并使用生物制剂是临床缓解的预测因素。
  • 甲氨蝶呤可降低炎症标志物及铁蛋白水平,并显著减少糖皮质激素用量,36.7%患者停用糖皮质激素。

核心结论

  • 描述了接受甲氨蝶呤治疗的斯蒂尔病患者的临床特征,主要以关节表现和发热为主,无突出的多器官受累。
  • 甲氨蝶呤在降低疾病活动度、降低炎症标志物以及作为糖皮质激素节约剂方面具有临床实用性。
  • 38.6%的患者在研究结束时被判定为临床缓解,合并使用生物制剂是临床缓解的预测因素。
  • 男性性别似乎是停用糖皮质激素的预测因素。

研究设计与样本

  • 研究类型为来自AIDA网络斯蒂尔病登记处的真实世界研究。
  • 共纳入171例接受甲氨蝶呤治疗的斯蒂尔病患者,男性占43.3%,年龄37.1 ± 16.0岁。

主要发现

  • 甲氨蝶呤与糖皮质激素联用于68.4%的患者,与其他传统合成改善病情抗风湿药联用于6.4%,与生物制剂联用于25.1%。
  • 观察到改良系统性评分显著降低,38.6%的患者在研究结束时被判定为临床缓解。
  • 合并使用生物制剂是临床缓解的预测因素。
  • 甲氨蝶呤给药后观察到炎症标志物和铁蛋白水平降低。
  • 观察到糖皮质激素剂量显著减少,36.7%的患者停用了糖皮质激素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. METHODS: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. RESULTS: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. CONCLUSIONS: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ruscitti P, Sota J, Vitale A, et al. The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry. Semin Arthritis Rheum. 2023. PMID: 37517110. doi:10.1016/j.semarthrit.2023.152244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。